Skip Navigation LinksHome > May 2010 - Volume 29 - Issue 5 > IMMUNE RESPONSE AND ONE-YEAR ANTIBODY PERSISTENCE AFTER A FO...
Pediatric Infectious Disease Journal:
doi: 10.1097/INF.0b013e3181cdd379
Brief Reports

IMMUNE RESPONSE AND ONE-YEAR ANTIBODY PERSISTENCE AFTER A FOURTH DOSE OF A NOVEL HAEMOPHILUS INFLUENZAE TYPE B AND NEISSERIA MENINGITIDIS SEROGROUPS C AND Y-TETANUS TOXOID CONJUGATE VACCINE (HibMenCY) AT 12 TO 15 MONTHS OF AGE

Marshall, Gary S. MD*; Marchant, Colin D. MD†; Blatter, Mark MD‡; Aris, Emmanuel PhD§¶; Boutriau, Dominique MD§¶; Poolman, Jan T. PhD§¶; Friedland, Leonard R. MD§¶; Miller, Jacqueline M. MD§¶

Supplemental Author Material
Collapse Box

Abstract

A total of 236 infants received a fourth Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY) dose at 12 to 15 months. One month later, the proportion with anti–PRP antibody ≥1.0 μg/mL and bactericidal titers ≥1:8 to MenC and MenY was 98.9%, 96.9%, and 95.4%, respectively. One year later, anti-PRP concentrations ≥0.15 μg/mL, and MenC and MenY bactericidal titers ≥1:8 persisted in 100%, 96.6%, and 83.8%, respectively. The safety profile of HibMenCY was comparable to Hib.

© 2010 Lippincott Williams & Wilkins, Inc.

Login

Article Tools

Share

Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.